臓器保存市場 – 2030年までの世界予測

本レポートは、臓器保存市場を分析し、ソリューション、技術、臓器の種類、エンドユーザー、地域といった様々なセグメントに基づいて、市場規模と将来の成長可能性を予測することを目的としています。また、市場で入手可能な様々な臓器保存製品の製品ポートフォリオマトリックスも掲載しています。さらに、この市場における主要企業の競合分析に加え、各社の企業概要、製品ラインナップ、主要な市場戦略についても提供しています。

The global organ preservation market is projected to reach USD 0.3 billion by 2030 from USD 0.2 million in 2025, at a CAGR of 6.8% during the forecast period.

世界の臓器保存市場は、予測期間中に6.8%のCAGRで成長し、2025年の20万米ドルから2030年には3億米ドルに達すると予測されています。

The primary objective of organ preservation solutions and devices is to maintain the viability and functionality of organs between procurement and transplantation. Several factors fuel consistent growth in this market, including the increasing volume of organ transplants globally, technological advancements in preservation techniques, and the introduction of specialized solutions such as hypothermic and normothermic machine perfusion systems. The growing incidence of chronic diseases such as end-stage renal and liver failure is driving the demand for organ transplants, which in turn boosts the need for effective preservation technologies.

臓器保存ソリューションおよびデバイスの主目的は、臓器の採取から移植までの間、臓器の生存能力と機能性を維持することです。この市場の着実な成長を支えている要因としては、世界的な臓器移植件数の増加、保存技術の技術的進歩、そして低体温および常温機械灌流システムといった特殊なソリューションの導入などが挙げられます。末期腎不全や肝不全といった慢性疾患の発生率増加は臓器移植の需要を牽引しており、効果的な保存技術の必要性が高まっています。

By solution type, the University of Wisconsin (UW) segment accounted for the largest market share in 2024.

The market is categorized into UW, Custodiol HTK, Perfadex, and other solutions by solution type. In 2024, the University of Wisconsin (UW) solution accounted for the largest market share owing to high adoption and features such as proven efficacy in preserving organs like the liver, kidneys, and pancreas. It was the first introduced intracellular preservation solution and is widely regarded as the global benchmark for organ preservation. Its established clinical outcomes and reliability have solidified its position as the preferred choice among transplant surgeons and healthcare facilities.

By technique, the normothermic machine perfusion segment is expected to register the highest CAGR during the forecast period.

The normothermic machine perfusion segment is expected to grow at the highest CAGR during the forecast period. This technique simulates natural physiological conditions by maintaining normal body temperature and supplying essential nutrients and oxygen to the organ. It supports cellular function and metabolism throughout the preservation period. Normothermic perfusion helps maintain organ viability and minimizes inflammatory responses and ischemic injury, particularly in liver transplants. It is vital in improving graft regeneration and has been associated with better outcomes in transplant cases involving extended criteria donors, such as older individuals or those with comorbidities. As a result, its relevance is growing among transplant professionals seeking to optimize long-term graft survival and function.

By organ type, the lungs segment is expected to grow at the highest CAGR during the forecast period.

The lungs segment is expected to grow at the highest CAGR during the forecast period. Lung transplantation is regarded as the preferred treatment for patients with end-stage lung diseases such as chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis, or cystic fibrosis, all of which contribute to the growth of this segment. Other common causes of end-stage lung disease in adult patients include alpha-1 antitrypsin deficiency and pulmonary hypertension. With the increasing prevalence of respiratory illnesses, the number of patients requiring lung transplants is anticipated to rise, thereby driving demand for lung transplants. Additionally, advancements in graft survival and long-term graft function have established lung transplantation as a vital and often life-saving therapeutic option.

By end user, the specialty clinics segment is expected to grow at the highest CAGR during the forecast period.

The organ preservation market is segmented by end-users into organ transplant centers, hospitals, and specialty clinics. The specialty clinics segment is projected to grow at the highest CAGR in the organ preservation market due to their increasing role in transplant procedures and post-operative care. These clinics offer focused expertise, faster turnaround times, and advanced technologies tailored to organ preservation needs. Additionally, growing patient preference for specialized care and the rise in private healthcare investments further accelerate their growth in this segment.

By region, the Asia Pacific is expected to grow at the highest CAGR during the forecast period.

The Asia Pacific region is projected to grow at the highest CAGR during the forecast period. The high growth rate of this segment is primarily attributed to the combination of favorable government policies, increased public awareness, and a higher number of organ donations. For instance, China has seen its donation rates improve thanks to intensified public education, mobilization efforts, and technological advancements in organ transplants. Meanwhile, India’s rapid development in healthcare infrastructure has supported market growth and fostered medical tourism. Even with religious considerations, Japan has observed an improvement in organ donation due to a higher willingness to donate organs.

The breakdown of primary participants was as mentioned below:

• By Company Type – Tier 1–35%, Tier 2–45%, and Tier 3–20%
• By Designation – C-level–35%, Director-level–25%, Others–40%
• By Region – North America–45%, Europe–30%, Asia Pacific–20%, Latin America- 3%, the Middle East & Africa–1%, and GCC countries—1%

Key Players in the Organ Preservation Market

The key players operating in the organ preservation market include Paragonix Technologies (US), XVIVO Perfusion AB (Sweden), Dr. Franz Köhler Chemie GmbH (Germany), Essential Pharmaceuticals, LLC (US), TransMedics (US), OrganOx Limited (UK), 21st Century Medicine (US), Shanghai Genext Medical Technology (China), Bridge to Life Limited (US), Waters Medical Systems (US), Preservation Solutions (US), Carnamedica (Poland), Transplant Biomedicals (Spain), Institut Georges Lopez (France), Global Transplant Solutions (US), Avionord (Italy), Organ Preservation Solutions (England), EBERS (Spain), S.A.L.F. (Italy), Biochefa (Poland), Vascular Perfusion Solutions (US), and TX Innovations (Netherlands).

Research Coverage:

The report analyzes the organ preservation market and aims to estimate the market size and future growth potential based on various segments such as solution, technique, organ type, end user, and region. The report also includes a product portfolio matrix of various organ preservation products available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies.

Reasons to Buy the Report

The report will enrich established firms and new entrants/smaller firms to gauge the market’s pulse, which in turn would help them garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.

This report provides insights into the following pointers:

Analysis of key drivers (Ascending cases of multiple organ failure and growth in the geriatric population, the increasing initiatives to promote public awareness and encourage organ donation, the rising number of organ donors boost adoption of solid organ transplantation procedures); restraints (High cost of organ transplantation and religious concerns and misconceptions associated to organ donation); opportunities (the increasing focus on healthcare investments); and challenges (Significant gap between the number of organs donated and organs required annually coupled with the development of artificial organs)

• Market Penetration: Comprehensive information on product portfolios offered by the top players in the global organ preservation market. The report analyzes this market by solution, technique, organ type, and end user.
• Product Enhancement/Innovation: Detailed insights on upcoming trends and product launches in the global organ preservation market
• Market Development: Comprehensive information on the lucrative emerging markets by solution type, technique, organ type, and end user
• Market Diversification: Exhaustive information about new products or product enhancements, growing geographies, recent developments, and investments in the global organ preservation market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, competitive leadership mapping, and capabilities of leading players in the global organ preservation market.

Table of Contents

1               INTRODUCTION              24

1.1           STUDY OBJECTIVES       24

1.2           MARKET DEFINITION   24

1.2.1        INCLUSIONS AND EXCLUSIONS 25

1.3           MARKET SCOPE                25

1.3.1        MARKET SEGMENTATION & REGIONAL SCOPE 25

1.3.2        YEARS CONSIDERED      26

1.4           CURRENCY CONSIDERED            26

1.5           SUMMARY OF CHANGES               27

2               RESEARCH METHODOLOGY       28

2.1           RESEARCH APPROACH  28

2.2           RESEARCH DESIGN         28

2.2.1        SECONDARY RESEARCH                29

2.2.1.1    Key data from secondary sources       30

2.2.2        PRIMARY DATA 30

2.2.2.1    Key data from primary sources           32

2.2.2.2    Key industry insights           33

2.3           MARKET SIZE ESTIMATION         35

2.4           MARKET BREAKDOWN & DATA TRIANGULATION                 41

2.5           MARKET RANKING ANALYSIS     42

2.6           RESEARCH ASSUMPTIONS           42

2.7           RESEARCH LIMITATIONS             42

2.7.1        METHODOLOGY-RELATED LIMITATIONS           42

2.7.2        SCOPE-RELATED LIMITATIONS                 42

2.8           RISK ASSESSMENT           42

3               EXECUTIVE SUMMARY  43

4               PREMIUM INSIGHTS       47

4.1           ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN ORGAN PRESERVATION MARKET              47

4.2           ASIA PACIFIC: ORGAN PRESERVATION MARKET,  BY SOLUTION AND COUNTRY          48

4.3           ORGAN PRESERVATION MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES         49

4.4           ORGAN PRESERVATION MARKET, BY REGION, 2023–2030                 49

4.5           ORGAN PRESERVATION MARKET:  DEVELOPED VS. EMERGING MARKETS    50

5               MARKET OVERVIEW       51

5.1           INTRODUCTION              51

5.2           MARKET DYNAMICS       51

5.2.1        DRIVERS               52

5.2.1.1    Growing geriatric population and subsequent growth in cases of multiple organ failure           52

5.2.1.2    Increasing initiatives to promote public awareness and encourage organ donation      52

5.2.1.3    Rising number of organ donors and growing adoption of solid organ transplantation procedures      53

5.2.2        RESTRAINTS      54

5.2.2.1    High cost of organ transplantation    54

5.2.2.2    Religious concerns and misconceptions associated with organ donation 54

5.2.3        OPPORTUNITIES              55

5.2.3.1    Growing healthcare investments        55

5.2.4        CHALLENGES    56

5.2.4.1    Significant gap between number of organs donated and organs required annually 56

5.2.4.2    Development of artificial organs        56

5.3           ECOSYSTEM ANALYSIS  57

5.4           VALUE CHAIN ANALYSIS               57

5.5           PRICING ANALYSIS          58

5.6           SUPPLY CHAIN ANALYSIS             59

5.7           PATENT ANALYSIS          60

5.7.1        PATENT PUBLICATION TRENDS FOR ORGAN PRESERVATION MARKET              60

5.7.2        TOP APPLICANTS (COMPANIES) OF ORGAN PRESERVATION PATENTS            61

5.7.3        JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR PATENTS IN ORGAN PRESERVATION MARKET               61

5.8           TECHNOLOGY ANALYSIS             63

5.8.1        KEY TECHNOLOGIES     63

5.8.1.1    Machine perfusion                63

5.8.1.2    Organ perfusion   64

5.8.2        ADJACENT TECHNOLOGIES       64

5.8.2.1    Cryopreservation & vitrification         64

5.8.3        COMPLEMENTARY TECHNOLOGIES       64

5.8.3.1    Temperature monitoring devices       64

5.9           TRADE ANALYSIS             65

5.9.1        IMPORT DATA  65

5.9.2        EXPORT DATA  65

5.10         KEY CONFERENCES AND EVENTS IN 2025–2026   66

5.11         REGULATORY LANDSCAPE         66

5.11.1      REGULATORY ANALYSIS               66

5.11.1.1  North America      66

5.11.1.1.1                US           66

5.11.1.1.2                Canada   66

5.11.1.2  Europe   66

5.11.1.3  Asia Pacific            67

5.11.1.3.1                China      67

5.11.1.3.2                Japan      67

5.11.1.3.3                India       67

5.11.1.4  Latin America       67

5.11.1.4.1                Brazil      67

5.11.1.4.2                Mexico   68

5.11.1.5  Middle East           68

5.11.1.6  Africa      68

5.11.2      REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS             68

5.12         PORTER’S FIVE FORCES ANALYSIS           70

5.12.1      THREAT FROM NEW ENTRANTS                70

5.12.2      THREAT FROM SUBSTITUTES   71

5.12.3      BARGAINING POWER OF SUPPLIERS       71

5.12.4      BARGAINING POWER OF BUYERS             71

5.12.5      INTENSITY OF COMPETITIVE RIVALRY 71

5.13         KEY STAKEHOLDERS AND BUYING CRITERIA     72

5.13.1      KEY STAKEHOLDERS IN BUYING PROCESS           72

5.13.2      BUYING CRITERIA           72

5.14         TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS            73

5.15         CASE STUDY ANALYSIS 74

5.16         INVESTMENT AND FUNDING SCENARIO               75

5.17         REIMBURSEMENT SCENARIO     75

5.18         IMPACT OF AI ON ORGAN PRESERVATION MARKET                 76

5.19         END USER EXPECTATIONS IN ORGAN PRESERVATION MARKET               77

5.20         IMPACT OF 2025 US TARIFFS      78

5.20.1      INTRODUCTION              78

5.20.2      KEY TARIFF RATES          79

5.20.3      PRICE IMPACT ANALYSIS             79

5.20.4      IMPACT ON END USERS                80

6               ORGAN PRESERVATION MARKET, BY SOLUTION                 81

6.1           INTRODUCTION              82

6.2           UNIVERSITY OF WISCONSIN       83

6.2.1        METABOLICALLY INERT SUBSTRATES ENABLE BETTER TRANSPLANTATION OUTCOMES             83

6.3           CUSTODIOL HTK             85

6.3.1        INDICATED FOR PERFUSION AND FLUSHING OF KIDNEYS, LIVER, PANCREAS, AND HEART             85

6.4           PERFADEX          86

6.4.1        LAUNCH OF PERFADEX PLUS TO DRIVE MARKET                 86

6.5           OTHER SOLUTIONS        87

7               ORGAN PRESERVATION MARKET, BY TECHNIQUE                 89

7.1           INTRODUCTION              90

7.2           STATIC COLD STORAGE               92

7.2.1        MOST WIDELY ADOPTED ORGAN PRESERVATION TECHNIQUE       92

7.3           HYPOTHERMIC MACHINE PERFUSION  94

7.3.1        ADVANTAGES ASSOCIATED WITH HYPOTHERMIC MACHINE PERFUSION TO DRIVE DEMAND          94

7.4           NORMOTHERMIC MACHINE PERFUSION              96

7.4.1        PROVIDES VIABLE ENVIRONMENT FOR ORGAN PRESERVATION, VIABILITY, AND REPAIR PRIOR TO TRANSPLANTATION      96

8               ORGAN PRESERVATION MARKET, BY ORGAN TYPE                 98

8.1           INTRODUCTION              99

8.2           KIDNEYS              99

8.2.1        MOST TRANSPLANTED ORGANS GLOBALLY       99

8.3           LIVER    100

8.3.1        RISING PREVALENCE OF LIVER DISEASE AND GROWING CASES OF LIVER FAILURE TO DRIVE DEMAND FOR LIVER TRANSPLANTATION PROCEDURES         100

8.4           LUNGS  102

8.4.1        GROWTH IN COPD INCIDENCE TO BOOST DEMAND FOR PRESERVATION TECHNIQUES AND PRODUCTS       102

8.5           HEART  103

8.5.1        ADVANCEMENTS IN HEART PRESERVATION TECHNIQUES TO DRIVE MARKET             103

8.6           OTHER ORGANS               104

9               ORGAN PRESERVATION MARKET, BY END USER                 106

9.1           INTRODUCTION              107

9.2           ORGAN TRANSPLANT CENTERS                107

9.2.1        MAJOR END USERS OF ORGAN PRESERVATION SOLUTIONS        107

9.3           HOSPITALS         108

9.3.1        INCREASING CASES OF ACCIDENTAL INJURIES AND CHRONIC DISEASES TO DRIVE MARKET                108

9.4           SPECIALTY CLINICS        110

9.4.1        INCREASING PREVALENCE OF END-STAGE DISEASES AND ORGAN FAILURE TO DRIVE MARKET            110

10            ORGAN PRESERVATION MARKET, BY REGION   111

10.1         INTRODUCTION              112

10.2         NORTH AMERICA             113

10.2.1      MACROECONOMIC OUTLOOK  113

10.2.2      US           116

10.2.2.1  Growing cases of organ failure and underlying diseases to drive demand  116

10.2.3      CANADA               119

10.2.3.1  Improved organ donation rates to drive growth               119

10.3         EUROPE               122

10.3.1      MACROECONOMIC OUTLOOK  122

10.3.2      GERMANY           125

10.3.2.1  Growing patient population to drive demand  125

10.3.3      FRANCE                127

10.3.3.1  Increasing number of organ transplants and organ donor registrations to drive growth               127

10.3.4      UK          129

10.3.4.1  Increasing disease/disorder prevalence and favorable regulations to drive demand    129

10.3.5      SPAIN    132

10.3.5.1  High donation rates to drive growth 132

10.3.6      ITALY    134

10.3.6.1  Surge in donor numbers and technological innovation to drive growth    134

10.3.7      REST OF EUROPE             136

10.4         ASIA PACIFIC     138

10.4.1      MACROECONOMIC OUTLOOK  139

10.4.2      CHINA  143

10.4.2.1  Growing awareness and adoption of laws favoring organ donation to drive market      143

10.4.3      JAPAN   145

10.4.3.1  Nationwide awareness campaigns and promoted opt-in registration to drive growth                 145

10.4.4      INDIA    148

10.4.4.1  Growing number of initiatives to increase public awareness to drive market          148

10.4.5      AUSTRALIA         150

10.4.5.1  Enhanced hospital-based donation programs to drive growth                 150

10.4.6      SOUTH KOREA  152

10.4.6.1  Improved donor registration systems to drive growth    152

10.4.7      REST OF ASIA PACIFIC   154

10.5         LATIN AMERICA                156

10.5.1      MACROECONOMIC OUTLOOK  157

10.5.2      BRAZIL 159

10.5.2.1  Digitalization of donor registries to drive growth            159

10.5.3      MEXICO                161

10.5.3.1  Organ donation efforts supported by centralized transplant registry and national coordination to drive growth         161

10.5.4      REST OF LATIN AMERICA             163

10.6         MIDDLE EAST & AFRICA                165

10.6.1      IMPLEMENTATION OF GOVERNMENT INITIATIVES AND POLICIES TO DRIVE MARKET           165

10.6.2      MACROECONOMIC OUTLOOK  166

10.7         GCC COUNTRIES              168

10.7.1      STRONG ORGAN PRESERVATION THROUGH INCENTIVES, INFRASTRUCTURE, AND PUBLIC AWARENESS TO DRIVE GROWTH               168

10.7.2      MACROECONOMIC OUTLOOK  169

11            COMPETITIVE LANDSCAPE         172

11.1         OVERVIEW          172

11.2         KEY PLAYER STRATEGIES/RIGHT TO WIN            172

11.3         REVENUE ANALYSIS, 2022–2024  174

11.4         MARKET SHARE ANALYSIS           175

11.5         COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024                 177

11.5.1      STARS   177

11.5.2      EMERGING LEADERS     177

11.5.3      PERVASIVE PLAYERS      178

11.5.4      PARTICIPANTS 178

11.5.5      COMPANY FOOTPRINT: KEY PLAYERS, 2024         179

11.5.5.1  Company footprint               179

11.5.5.2  Solution footprint 180

11.5.5.3  Technique footprint             181

11.5.5.4  End user footprint                 182

11.5.5.5  Region footprint   183

11.6         COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024        184

11.6.1      PROGRESSIVE COMPANIES         184

11.6.2      RESPONSIVE COMPANIES            184

11.6.3      DYNAMIC COMPANIES  184

11.6.4      STARTING BLOCKS         184

11.6.5      COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024                 185

11.6.5.1  List of key startups/SMEs  185

11.6.5.2  Competitive benchmarking of key startups/SMEs          186

11.7         COMPANY VALUATION AND FINANCIAL METRICS                 186

11.7.1      COMPANY VALUATION 186

11.7.2      FINANCIAL METRICS      187

11.8         BRAND/PRODUCT COMPARISON             187

11.9         COMPETITIVE SCENARIO             188

11.9.1      PRODUCT LAUNCHES & APPROVALS     188

11.9.2      DEALS  189

11.9.3      OTHER DEVELOPMENTS              190

12            COMPANY PROFILES      191

12.1         KEY PLAYERS     191

12.1.1      PARAGONIX TECHNOLOGIES, INC.          191

12.1.1.1  Business overview 191

12.1.1.2  Products offered   191

12.1.1.3  Recent developments           192

12.1.1.3.1                Product launches  192

12.1.1.3.2                Deals      193

12.1.1.3.3                Other developments             194

12.1.1.4  MnM view              194

12.1.1.4.1                Right to win           194

12.1.1.4.2                Strategic choices   194

12.1.1.4.3                Weaknesses and competitive threats 195

12.1.2      XVIVO PERFUSION AB   196

12.1.2.1  Business overview 196

12.1.2.2  Products offered   197

12.1.2.3  Recent developments           198

12.1.2.3.1                Product launches & approvals            198

12.1.2.3.2                Deals      199

12.1.2.4  MnM view              199

12.1.2.4.1                Right to win           199

12.1.2.4.2                Strategic choices   200

12.1.2.4.3                Weaknesses and competitive threats 200

12.1.3      DR. FRANZ KÖHLER CHEMIE GMBH        201

12.1.3.1  Business overview 201

12.1.3.2  Products offered   201

12.1.3.3  MnM view              202

12.1.3.3.1                Right to win           202

12.1.3.3.2                Strategic choices   202

12.1.3.3.3                Weaknesses and competitive threats 202

12.1.4      ESSENTIAL PHARMACEUTICALS, LLC (SUBSIDIARY OF ACCORD HEALTHCARE)               203

12.1.4.1  Business overview 203

12.1.4.2  Products offered   203

12.1.4.3  MnM view              204

12.1.4.3.1                Right to win           204

12.1.4.3.2                Strategic choices   204

12.1.4.3.3                Weaknesses and competitive threats 204

12.1.5      TRANSMEDICS, INC.       205

12.1.5.1  Business overview 205

12.1.5.2  Products offered   206

12.1.5.3  Recent developments           206

12.1.5.3.1                Product launches & approvals            206

12.1.5.3.2                Deals      206

12.1.5.4  MnM view              207

12.1.5.4.1                Right to win           207

12.1.5.4.2                Strategic choices   207

12.1.5.4.3                Weaknesses and competitive threats 207

12.1.6      ORGANOX LIMITED        208

12.1.6.1  Business overview 208

12.1.6.2  Products offered   208

12.1.6.3  Recent developments           208

12.1.6.3.1                Product launches & approvals            208

12.1.6.3.2                Deals      209

12.1.7      21ST CENTURY MEDICINE           210

12.1.7.1  Business overview 210

12.1.7.2  Products offered   210

12.1.8      BIOLIFE SOLUTIONS, INC.            211

12.1.8.1  Business overview 211

12.1.8.2  Products offered   212

12.1.8.3  Recent developments           212

12.1.8.3.1                Product launches  212

12.1.8.3.2                Deals      213

12.1.9      BRIDGE TO LIFE LIMITED            214

12.1.9.1  Business overview 214

12.1.9.2  Products offered   214

12.1.9.3  Recent developments           215

12.1.9.3.1                Product launches & approvals            215

12.1.9.3.2                Deals      215

12.1.10   WATERS MEDICAL SYSTEMS LLC              216

12.1.10.1                 Business overview 216

12.1.10.2                 Products offered   216

12.2         OTHER PLAYERS              217

12.2.1      SHANGHAI GENEXT MEDICAL TECHNOLOGY CO., LTD.                 217

12.2.2      PRESERVATION SOLUTIONS, INC.            218

12.2.3      CARNAMEDICA 219

12.2.4      TRANSPLANT BIOMEDICALS     220

12.2.5      INSTITUT GEORGES LOPEZ        221

12.2.6      GLOBAL TRANSPLANT SOLUTIONS        222

12.2.7      AVIONORD         222

12.2.8      ORGAN PRESERVATION SOLUTIONS LTD.           223

12.2.9      EBERS   223

12.2.10   S.A.L.F. 224

12.2.11   BIOCHEFA           224

12.2.12   VASCULAR PERFUSION SOLUTIONS, INC.             225

12.2.13   TX INNOVATIONS           225

12.2.14   TAIYO NIPPON SANSO CORPORATION  226

12.2.15   X-THERMA, INC.               226

13            APPENDIX           227

13.1         DISCUSSION GUIDE        227

13.2         KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL                231

13.3         AVAILABLE CUSTOMIZATIONS 233

13.4         RELATED REPORTS         233

13.5         AUTHOR DETAILS           234

LIST OF TABLES

TABLE 1                EXCHANGE RATES UTILIZED FOR CONVERSION TO USD, 2021–2024           26

TABLE 2                GROWTH IN GERIATRIC POPULATION (ABOVE 65 AGE GROUP), BY REGION,

2019 VS. 2050 (MILLION)                52

TABLE 3                NUMBER OF ORGAN DONATIONS, 2020 54

TABLE 4                COST OF SURGICAL PROCEDURES: US VS. INDIA (USD)    55

TABLE 5                AVERAGE SELLING PRICE RANGE OF ORGAN PRESERVATION SOLUTIONS,

BY KEY PLAYERS, 2023–2024          58

TABLE 6                AVERAGE SELLING PRICE RANGE OF CUSTODIOL SOLUTIONS FOR ORGAN PRESERVATION SOLUTIONS IN KEY REGIONS, 2022–2024                 59

TABLE 7                ORGAN PRESERVATION MARKET: LIST OF MAJOR PATENTS, 2020–2021         62

TABLE 8                IMPORT DATA OF ORGAN PRESERVATION FOR HS CODE 300640, BY COUNTRY,  2019–2023 (USD THOUSAND)                 65

TABLE 9                EXPORT DATA OF ORGAN PRESERVATION FOR HS CODE 300640, BY COUNTRY,  2019–2023 (USD THOUSAND)                 65

TABLE 10              NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND  OTHER ORGANIZATIONS                 68

TABLE 11              ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 69

TABLE 12              LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND  OTHER ORGANIZATIONS                 69

TABLE 13              REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND  OTHER ORGANIZATIONS                 69

TABLE 14              INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP 3 SOLUTIONS (%)     72

TABLE 15              KEY BUYING CRITERIA FOR TOP 3 SOLUTIONS                 73

TABLE 16              CASE STUDY 1: PRESERVATION OF MARGINAL LIVER USING NORMOTHERMIC MACHINE PERFUSION (NMP)                 74

TABLE 17              CASE STUDY 2: HYPOTHERMIC MACHINE PERFUSION FOR EXTENDED CRITERIA KIDNEY TRANSPLANT                 74

TABLE 18              CASE STUDY 3: USE OF PORTABLE NORMOTHERMIC PERFUSION FOR HEART TRANSPLANTATION                 75

TABLE 19              US-ADJUSTED RECIPROCAL TARIFF RATES                 79

TABLE 20              ORGAN PRESERVATION MARKET, BY SOLUTION, 2023–2030 (USD MILLION)    82

TABLE 21              ORGAN PRESERVATION SOLUTIONS MARKET, BY COUNTRY/REGION,

2023–2030 (USD MILLION)            83

TABLE 22              ORGAN PRESERVATION MARKET FOR UW SOLUTIONS, BY COUNTRY/REGION,  2023–2030 (USD MILLION)                 84

TABLE 23              ORGAN PRESERVATION MARKET FOR CUSTODIOL HTK SOLUTIONS, BY COUNTRY/ REGION, 2023–2030 (USD MILLION)       86

TABLE 24              ORGAN PRESERVATION MARKET FOR PERFADEX SOLUTIONS,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            87

TABLE 25              OTHER ORGAN PRESERVATION SOLUTIONS MARKET, BY COUNTRY/REGION,  2023–2030 (USD MILLION)                 88

TABLE 26              COMPARISON OF METHODS USED FOR ORGAN PRESERVATION                90

TABLE 27              ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 90

TABLE 28              ORGAN PRESERVATION TECHNIQUE MARKET, BY COUNTRY/REGION,

2023–2030 (USD MILLION)            91

TABLE 29              STATIC COLD STORAGE: ADVANTAGES AND DISADVANTAGES            92

TABLE 30              ORGAN PRESERVATION MARKET FOR STATIC COLD STORAGE,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            93

TABLE 31              HYPOTHERMIC MACHINE PERFUSION: ADVANTAGES AND DISADVANTAGES   94

TABLE 32              ORGAN PRESERVATION MARKET FOR HYPOTHERMIC MACHINE PERFUSION,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            95

TABLE 33              NORMOTHERMIC MACHINE PERFUSION: ADVANTAGES AND DISADVANTAGES   96

TABLE 34              ORGAN PRESERVATION MARKET FOR NORMOTHERMIC MACHINE PERFUSION,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            97

TABLE 35              ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2023–2030 (USD MILLION)                99

TABLE 36              KIDNEY PRESERVATION MARKET, BY COUNTRY/REGION,

2023–2030 (USD MILLION)            100

TABLE 37              LIVER PRESERVATION MARKET, BY COUNTRY/REGION,

2023–2030 (USD MILLION)            101

TABLE 38              LUNG PRESERVATION MARKET, BY COUNTRY/REGION,

2023–2030 (USD MILLION)            103

TABLE 39              HEART PRESERVATION MARKET, BY COUNTRY/REGION,

2023–2030 (USD MILLION)            104

TABLE 40              OTHER ORGAN PRESERVATION MARKET, BY COUNTRY/REGION,

2023–2030 (USD MILLION)            105

TABLE 41              ORGAN PRESERVATION MARKET, BY END USER, 2023–2030 (USD MILLION)            107

TABLE 42              ORGAN PRESERVATION MARKET FOR ORGAN TRANSPLANT CENTERS,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            108

TABLE 43              ORGAN PRESERVATION MARKET FOR HOSPITALS, BY COUNTRY/REGION,

2023–2030 (USD MILLION)            109

TABLE 44              ORGAN PRESERVATION MARKET FOR SPECIALTY CLINICS, BY COUNTRY/REGION,  2023–2030 (USD MILLION)            110

TABLE 45              ORGAN PRESERVATION MARKET, BY REGION, 2023–2030 (USD MILLION)            113

TABLE 46              NORTH AMERICA: ORGAN PRESERVATION MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            115

TABLE 47              NORTH AMERICA: ORGAN PRESERVATION MARKET, BY TECHNIQUE,

2023–2030 (USD MILLION)          115

TABLE 48              NORTH AMERICA: ORGAN PRESERVATION MARKET, BY SOLUTION,

2023–2030 (USD MILLION)            115

TABLE 49              NORTH AMERICA: ORGAN PRESERVATION MARKET, BY ORGAN TYPE,

2023–2030 (USD MILLION)            116

TABLE 50              NORTH AMERICA: ORGAN PRESERVATION MARKET, BY END USER,

2023–2030 (USD MILLION)            116

TABLE 51              US: KEY MACROINDICATORS     117

TABLE 52              WAITING LIST FOR ORGAN TRANSPLANTS AS OF JANUARY 2022             117

TABLE 53              US: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 118

TABLE 54              US: ORGAN PRESERVATION MARKET, BY SOLUTION, 2023–2030 (USD MILLION)    118

TABLE 55              US: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2023–2030 (USD MILLION)               119

TABLE 56              US: ORGAN PRESERVATION MARKET, BY END USER, 2023–2030 (USD MILLION)                119

TABLE 57              CANADA: KEY MACROINDICATORS         120

TABLE 58              CANADA: ORGAN PRESERVATION MARKET, BY TECHNIQUE,

2023–2030 (USD MILLION)            120

TABLE 59              CANADA: ORGAN PRESERVATION MARKET, BY SOLUTION,

2023–2030 (USD MILLION)            121

TABLE 60              CANADA: ORGAN PRESERVATION MARKET, BY ORGAN TYPE,

2023–2030 (USD MILLION)            121

TABLE 61              CANADA: ORGAN PRESERVATION MARKET, BY END USER,

2023–2030 (USD MILLION)            121

TABLE 62              EUROPE: ORGAN PRESERVATION MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            123

TABLE 63              EUROPE: ORGAN PRESERVATION MARKET, BY TECHNIQUE,

2023–2030 (USD MILLION)            123

TABLE 64              EUROPE: ORGAN PRESERVATION MARKET, BY SOLUTION,

2023–2030 (USD MILLION)            124

TABLE 65              EUROPE: ORGAN PRESERVATION MARKET, BY ORGAN TYPE,

2023–2030 (USD MILLION)            124

TABLE 66              EUROPE: ORGAN PRESERVATION MARKET, BY END USER,

2023–2030 (USD MILLION)            125

TABLE 67              GERMANY: KEY MACROINDICATORS      126

TABLE 68              GERMANY: ORGAN PRESERVATION MARKET, BY TECHNIQUE,

2023–2030 (USD MILLION)            126

TABLE 69              GERMANY: ORGAN PRESERVATION MARKET, BY SOLUTION,

2023–2030 (USD MILLION)            126

TABLE 70              GERMANY: ORGAN PRESERVATION MARKET, BY ORGAN TYPE,

2023–2030 (USD MILLION)            127

TABLE 71              GERMANY: ORGAN PRESERVATION MARKET, BY END USER,

2023–2030 (USD MILLION)            127

TABLE 72              FRANCE: KEY MACROINDICATORS          128

TABLE 73              FRANCE: ORGAN PRESERVATION MARKET, BY TECHNIQUE,

2023–2030 (USD MILLION)            128

TABLE 74              FRANCE: ORGAN PRESERVATION MARKET, BY SOLUTION,

2023–2030 (USD MILLION)            128

TABLE 75              FRANCE: ORGAN PRESERVATION MARKET, BY ORGAN TYPE,

2023–2030 (USD MILLION)            129

TABLE 76              FRANCE: ORGAN PRESERVATION MARKET, BY END USER,

2023–2030 (USD MILLION)            129

TABLE 77              UK: KEY MACROINDICATORS     130

TABLE 78              TOTAL NUMBER OF PATIENTS ON ACTIVE ORGAN TRANSPLANT WAITING LIST IN

UK  (AS OF APRIL 8, 2021)            130

TABLE 79              UK: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 130

TABLE 80              UK: ORGAN PRESERVATION MARKET, BY SOLUTION, 2023–2030 (USD MILLION)    131

TABLE 81              UK: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2023–2030 (USD MILLION)               131

TABLE 82              UK: ORGAN PRESERVATION MARKET, BY END USER, 2023–2030 (USD MILLION)                131

TABLE 83              SPAIN: KEY MACROINDICATORS               132

TABLE 84              SPAIN: ORGAN PRESERVATION MARKET, BY TECHNIQUE,

2023–2030 (USD MILLION)            132

TABLE 85              SPAIN: ORGAN PRESERVATION MARKET, BY SOLUTION,

2023–2030 (USD MILLION)            133

TABLE 86              SPAIN: ORGAN PRESERVATION MARKET, BY ORGAN TYPE,

2023–2030 (USD MILLION)            133

TABLE 87              SPAIN: ORGAN PRESERVATION MARKET, BY END USER,

2023–2030 (USD MILLION)            134

TABLE 88              ITALY: KEY MACROINDICATORS               134

TABLE 89              ITALY: ORGAN PRESERVATION MARKET, BY TECHNIQUE,

2023–2030 (USD MILLION)            135

TABLE 90              ITALY: ORGAN PRESERVATION MARKET, BY SOLUTION, 2023–2030 (USD MILLION)    135

TABLE 91              ITALY: ORGAN PRESERVATION MARKET, BY ORGAN TYPE,

2023–2030 (USD MILLION)            136

TABLE 92              ITALY: ORGAN PRESERVATION MARKET, BY END USER,

2023–2030 (USD MILLION)            136

TABLE 93              REST OF EUROPE: ORGAN PRESERVATION MARKET, BY TECHNIQUE,

2023–2030 (USD MILLION)            137

TABLE 94              REST OF EUROPE: ORGAN PRESERVATION MARKET, BY SOLUTION,

2023–2030 (USD MILLION)            137

TABLE 95              REST OF EUROPE: ORGAN PRESERVATION MARKET, BY ORGAN TYPE,

2023–2030 (USD MILLION)            138

TABLE 96              REST OF EUROPE: ORGAN PRESERVATION MARKET, BY END USER,

2023–2030 (USD MILLION)            138

TABLE 97              ASIA PACIFIC: ORGAN PRESERVATION MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            141

TABLE 98              ASIA PACIFIC: ORGAN PRESERVATION MARKET, BY TECHNIQUE,

2023–2030 (USD MILLION)            141

TABLE 99              ASIA PACIFIC: ORGAN PRESERVATION MARKET, BY SOLUTION,

2023–2030 (USD MILLION)            142

TABLE 100            ASIA PACIFIC: ORGAN PRESERVATION MARKET, BY ORGAN TYPE,

2023–2030 (USD MILLION)            142

TABLE 101            ASIA PACIFIC: ORGAN PRESERVATION MARKET, BY END USER,

2023–2030 (USD MILLION)            143

TABLE 102            CHINA: ORGAN PRESERVATION MARKET, BY TECHNIQUE,

2023–2030 (USD MILLION)            144

TABLE 103            CHINA: ORGAN PRESERVATION MARKET, BY SOLUTION,

2023–2030 (USD MILLION)            144

TABLE 104            CHINA: ORGAN PRESERVATION MARKET, BY ORGAN TYPE,

2023–2030 (USD MILLION)            145

TABLE 105            CHINA: ORGAN PRESERVATION MARKET, BY END USER,

2023–2030 (USD MILLION)            145

TABLE 106            TOTAL NUMBER OF PATIENTS ON ORGAN TRANSPLANT WAITING LIST IN JAPAN  (AS OF MARCH 31, 2021)                 146

TABLE 107            JAPAN: ORGAN PRESERVATION MARKET, BY TECHNIQUE,

2023–2030 (USD MILLION)            146

TABLE 108            JAPAN: ORGAN PRESERVATION MARKET, BY SOLUTION,

2023–2030 (USD MILLION)            147

TABLE 109            JAPAN: ORGAN PRESERVATION MARKET, BY ORGAN TYPE,

2023–2030 (USD MILLION)            147

TABLE 110            JAPAN: ORGAN PRESERVATION MARKET, BY END USER,

2023–2030 (USD MILLION)            148

TABLE 111            INDIA: ORGAN PRESERVATION MARKET, BY TECHNIQUE,

2023–2030 (USD MILLION)            149

TABLE 112            INDIA: ORGAN PRESERVATION MARKET, BY SOLUTION, 2023–2030 (USD MILLION)    149

TABLE 113            INDIA: ORGAN PRESERVATION MARKET, BY ORGAN TYPE,

2023–2030 (USD MILLION)            150

TABLE 114            INDIA: ORGAN PRESERVATION MARKET, BY END USER,

2023–2030 (USD MILLION)            150

TABLE 115            AUSTRALIA: ORGAN PRESERVATION MARKET, BY TECHNIQUE,

2023–2030 (USD MILLION)            151

TABLE 116            AUSTRALIA: ORGAN PRESERVATION MARKET, BY SOLUTION,

2023–2030 (USD MILLION)            151

TABLE 117            AUSTRALIA: ORGAN PRESERVATION MARKET, BY ORGAN TYPE,

2023–2030 (USD MILLION)            152

TABLE 118            AUSTRALIA: ORGAN PRESERVATION MARKET, BY END USER,

2023–2030 (USD MILLION)            152

TABLE 119            SOUTH KOREA: ORGAN PRESERVATION MARKET, BY TECHNIQUE,

2023–2030 (USD MILLION)            153

TABLE 120            SOUTH KOREA: ORGAN PRESERVATION MARKET, BY SOLUTION,

2023–2030 (USD MILLION)            153

TABLE 121            SOUTH KOREA: ORGAN PRESERVATION MARKET, BY ORGAN TYPE,

2023–2030 (USD MILLION)            154

TABLE 122            SOUTH KOREA: ORGAN PRESERVATION MARKET, BY END USER,

2023–2030 (USD MILLION)            154

TABLE 123            REST OF ASIA PACIFIC: ORGAN PRESERVATION MARKET, BY TECHNIQUE,

2023–2030 (USD MILLION)            155

TABLE 124            REST OF ASIA PACIFIC: ORGAN PRESERVATION MARKET, BY SOLUTION,

2023–2030 (USD MILLION)            155

TABLE 125            REST OF ASIA PACIFIC: ORGAN PRESERVATION MARKET, BY ORGAN TYPE,

2023–2030 (USD MILLION)            156

TABLE 126            REST OF ASIA PACIFIC: ORGAN PRESERVATION MARKET, BY END USER,

2023–2030 (USD MILLION)            156

TABLE 127            LATIN AMERICA: ORGAN PRESERVATION MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            157

TABLE 128            LATIN AMERICA: ORGAN PRESERVATION MARKET, BY TECHNIQUE,

2023–2030 (USD MILLION)            158

TABLE 129            LATIN AMERICA: ORGAN PRESERVATION MARKET, BY SOLUTION,

2023–2030 (USD MILLION)            158

TABLE 130            LATIN AMERICA: ORGAN PRESERVATION MARKET, BY ORGAN TYPE,

2023–2030 (USD MILLION)            159

TABLE 131            LATIN AMERICA: ORGAN PRESERVATION MARKET, BY END USER,

2023–2030 (USD MILLION)            159

TABLE 132            BRAZIL: ORGAN PRESERVATION MARKET, BY TECHNIQUE,

2023–2030 (USD MILLION)            160

TABLE 133            BRAZIL: ORGAN PRESERVATION MARKET, BY SOLUTION,

2023–2030 (USD MILLION)            160

TABLE 134            BRAZIL: ORGAN PRESERVATION MARKET, BY ORGAN TYPE,

2023–2030 (USD MILLION)            161

TABLE 135            BRAZIL: ORGAN PRESERVATION MARKET, BY END USER,

2023–2030 (USD MILLION)            161

TABLE 136            MEXICO: ORGAN PRESERVATION MARKET, BY TECHNIQUE,

2023–2030 (USD MILLION)            162

TABLE 137            MEXICO: ORGAN PRESERVATION MARKET, BY SOLUTION,

2023–2030 (USD MILLION)            162

TABLE 138            MEXICO: ORGAN PRESERVATION MARKET, BY ORGAN TYPE,

2023–2030 (USD MILLION)            163

TABLE 139            MEXICO: ORGAN PRESERVATION MARKET, BY END USER,

2023–2030 (USD MILLION)            163

TABLE 140            REST OF LATIN AMERICA: ORGAN PRESERVATION MARKET, BY TECHNIQUE,  2023–2030 (USD MILLION)            164

TABLE 141            REST OF LATIN AMERICA: ORGAN PRESERVATION MARKET, BY SOLUTION,

2023–2030 (USD MILLION)            164

TABLE 142            REST OF LATIN AMERICA: ORGAN PRESERVATION MARKET, BY ORGAN TYPE,  2023–2030 (USD MILLION)            165

TABLE 143            REST OF LATIN AMERICA: ORGAN PRESERVATION MARKET, BY END USER,

2023–2030 (USD MILLION)            165

TABLE 144            MIDDLE EAST & AFRICA: ORGAN PRESERVATION MARKET, BY TECHNIQUE,

2023–2030 (USD MILLION)            166

TABLE 145            MIDDLE EAST & AFRICA: ORGAN PRESERVATION MARKET, BY SOLUTION,

2023–2030 (USD MILLION)            167

TABLE 146            MIDDLE EAST & AFRICA: ORGAN PRESERVATION MARKET, BY ORGAN TYPE,  2023–2030 (USD MILLION)            167

TABLE 147            MIDDLE EAST & AFRICA: ORGAN PRESERVATION MARKET, BY END USER,

2023–2030 (USD MILLION)            168

TABLE 148            GCC COUNTRIES: ORGAN PRESERVATION MARKET, BY TECHNIQUE,

2023–2030 (USD MILLION)            169

TABLE 149            GCC COUNTRIES: ORGAN PRESERVATION MARKET, BY SOLUTION,

2023–2030 (USD MILLION)            170

TABLE 150            GCC COUNTRIES: ORGAN PRESERVATION MARKET, BY ORGAN TYPE,

2023–2030 (USD MILLION)            170

TABLE 151            GCC COUNTRIES: ORGAN PRESERVATION MARKET, BY END USER,

2023–2030 (USD MILLION)            171

TABLE 152            OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN ORGAN PRESERVATION MARKET    173

TABLE 153            ORGAN PRESERVATION MARKET: DEGREE OF COMPETITION 176

TABLE 154            ORGAN PRESERVATION MARKET: SOLUTION FOOTPRINT       180

TABLE 155            ORGAN PRESERVATION MARKET: TECHNIQUE FOOTPRINT       181

TABLE 156            ORGAN PRESERVATION MARKET: END USER FOOTPRINT       182

TABLE 157            ORGAN PRESERVATION MARKET: REGION FOOTPRINT       183

TABLE 158            ORGAN PRESERVATION MARKET: LIST OF KEY STARTUPS/SMES              185

TABLE 159            ORGAN PRESERVATION MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES                 186

TABLE 160            ORGAN PRESERVATION MARKET: PRODUCT LAUNCHES & APPROVALS,

JANUARY 2021–JUNE 2025              188

TABLE 161            ORGAN PRESERVATION MARKET: DEALS, JANUARY 2021–JUNE 2025              189

TABLE 162            ORGAN PRESERVATION MARKET: OTHER DEVELOPMENTS,

JANUARY 2021–JUNE 2025              190

TABLE 163            PARAGONIX TECHNOLOGIES, INC.: COMPANY OVERVIEW          191

TABLE 164            PARAGONIX TECHNOLOGIES, INC.: PRODUCTS OFFERED             191

TABLE 165            PARAGONIX TECHNOLOGIES, INC.: PRODUCT LAUNCHES,

JANUARY 2021–MAY 2025               192

TABLE 166            PARAGONIX TECHNOLOGIES, INC.: DEALS, JANUARY 2021–MAY 2025               193

TABLE 167            PARAGONIX TECHNOLOGIES, INC.: OTHER DEVELOPMENTS,

JANUARY 2021–MAY 2025               194

TABLE 168            XVIVO PERFUSION AB: COMPANY OVERVIEW                 196

TABLE 169            XVIVO PERFUSION AB: PRODUCTS OFFERED                 197

TABLE 170            XVIVO PERFUSION AB: PRODUCT LAUNCHES & APPROVALS,

JANUARY 2021–MAY 2025               198

TABLE 171            XVIVO PERFUSION AB: DEALS, JANUARY 2021–MAY 2025              199

TABLE 172            DR. FRANZ KÖHLER CHEMIE GMBH: COMPANY OVERVIEW          201

TABLE 173            DR. FRANZ KÖHLER CHEMIE GMBH: PRODUCTS OFFERED             201

TABLE 174            ESSENTIAL PHARMACEUTICALS, LLC: COMPANY OVERVIEW   203

TABLE 175            ESSENTIAL PHARMACEUTICALS, LLC: PRODUCTS OFFERED    203

TABLE 176            TRANSMEDICS, INC.: COMPANY OVERVIEW                 205

TABLE 177            TRANSMEDICS, INC.: PRODUCTS OFFERED                 206

TABLE 178            TRANSMEDICS, INC.: PRODUCT LAUNCHES & APPROVALS        206

TABLE 179            TRANSMEDICS, INC.: DEALS       206

TABLE 180            ORGANOX LIMITED: COMPANY OVERVIEW                 208

TABLE 181            ORGANOX LIMITED: PRODUCTS OFFERED                 208

TABLE 182            ORGANOX LIMITED: PRODUCT LAUNCHES & APPROVALS        208

TABLE 183            ORGANOX LIMITED: DEALS        209

TABLE 184            21ST CENTURY MEDICINE: COMPANY OVERVIEW          210

TABLE 185            21ST CENTURY MEDICINE: PRODUCTS OFFERED             210

TABLE 186            BIOLIFE SOLUTIONS, INC.: COMPANY OVERVIEW          211

TABLE 187            BIOLIFE SOLUTIONS, INC.: PRODUCTS OFFERED             212

TABLE 188            BIOLIFE SOLUTIONS, INC.: PRODUCT LAUNCHES, JANUARY 2021–MAY 2025      212

TABLE 189            BIOLIFE SOLUTIONS, INC.: DEALS, JANUARY 2021–MAY 2025   213

TABLE 190            BRIDGE TO LIFE LIMITED: COMPANY OVERVIEW          214

TABLE 191            BRIDGE TO LIFE LIMITED: PRODUCTS OFFERED             214

TABLE 192            BRIDGE TO LIFE LIMITED: PRODUCT LAUNCHES & APPROVALS,

JANUARY 2021–MAY 2025               215

TABLE 193            BRIDGE TO LIFE LIMITED: DEALS, JANUARY 2021–MAY 2025   215

TABLE 194            WATERS MEDICAL SYSTEMS LLC: COMPANY OVERVIEW          216

TABLE 195            WATERS MEDICAL SYSTEMS LLC: PRODUCTS OFFERED             216

LIST OF FIGURES

FIGURE 1              ORGAN PRESERVATION MARKET: RESEARCH DESIGN                28

FIGURE 2              LIST OF PRIMARY SOURCES        31

FIGURE 3              BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS            33

FIGURE 4              BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION                34

FIGURE 5              BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION                34

FIGURE 6              SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS         35

FIGURE 7              REVENUE SHARE ANALYSIS ILLUSTRATION: XVIVO PERFUSION AB (2024)       36

FIGURE 8              ILLUSTRATIVE EXAMPLE OF PROCEDURE-BASED MARKET ESTIMATION    37

FIGURE 9              SUPPLY-SIDE MARKET SIZE ESTIMATION: ORGAN PRESERVATION MARKET (2024)                38

FIGURE 10            TOP-DOWN APPROACH                38

FIGURE 11            CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN ORGAN PRESERVATION MARKET  (2025–2030)  39

FIGURE 12            CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS                 40

FIGURE 13            DATA TRIANGULATION METHODOLOGY                 41

FIGURE 14            ORGAN PRESERVATION MARKET, BY SOLUTION, 2025 VS. 2030 (USD MILLION)              43

FIGURE 15            ORGAN PRESERVATION MARKET, BY TECHNIQUE,  2025 VS. 2030 (USD MILLION)       44

FIGURE 16            ORGAN PRESERVATION MARKET, BY ORGAN TYPE,  2025 VS. 2030 (USD MILLION)      44

FIGURE 17            ORGAN PRESERVATION MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)      45

FIGURE 18            GEOGRAPHIC ANALYSIS OF ORGAN PRESERVATION MARKET              46

FIGURE 19            RISING NUMBER OF SOLID ORGAN TRANSPLANTS TO DRIVE ORGAN PRESERVATION MARKET                 47

FIGURE 20            UNIVERSITY OF WISCONSIN SOLUTION AND CHINA SEGMENTS ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC ORGAN PRESERVATION MARKET IN 2024            48

FIGURE 21            CHINA TO REGISTER FASTEST GROWTH DURING FORECAST PERIOD       49

FIGURE 22            NORTH AMERICA TO DOMINATE ORGAN PRESERVATION MARKET TILL 2030          49

FIGURE 23            EMERGING MARKETS TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD    50

FIGURE 24            ORGAN PRESERVATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,

AND CHALLENGES          51

FIGURE 25            ORGAN PRESERVATION MARKET: ECOSYSTEM ANALYSIS            57

FIGURE 26            ORGAN PRESERVATION MARKET: VALUE CHAIN ANALYSIS              58

FIGURE 27            SUPPLY CHAIN ANALYSIS: ORGAN PRESERVATION MARKET (2024)                 59

FIGURE 28            TOP PATENT APPLICANTS AND OWNERS (COMPANIES/INSTITUTES) FOR ORGAN PRESERVATION SOLUTIONS (JANUARY 2014–APRIL 2025)               61

FIGURE 29            JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR ORGAN PRESERVATION PATENTS, 2014–2025                 61

FIGURE 30            ORGAN PRESERVATION MARKET: PORTER’S FIVE FORCES ANALYSIS 70

FIGURE 31            INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP 3 SOLUTIONS             72

FIGURE 32            KEY BUYING CRITERIA FOR TOP 3 SOLUTIONS                 72

FIGURE 33            TRENDS AND DISRUPTIONS DISRUPTING CUSTOMER BUSINESS IN ORGAN PRESERVATION MARKET                 73

FIGURE 34            ORGAN PRESERVATION MARKET: INVESTMENT AND FUNDING SCENARIO,

2021–2024              75

FIGURE 35            ORGAN PRESERVATION MARKET: AI INTEGRATION  77

FIGURE 38            ASIA PACIFIC: ORGAN PRESERVATION MARKET SNAPSHOT          140

FIGURE 39            REVENUE ANALYSIS OF KEY PLAYERS IN ORGAN PRESERVATION MARKET (2021−2024)    175

FIGURE 40            MARKET SHARE ANALYSIS OF KEY PLAYERS (2024)    175

FIGURE 41            ORGAN PRESERVATION MARKET: COMPANY EVALUATION MATRIX

(KEY PLAYERS), 2024       178

FIGURE 42            ORGAN PRESERVATION MARKET: COMPANY FOOTPRINT       179

FIGURE 43            ORGAN PRESERVATION MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 185

FIGURE 44            YEAR-TO-DATE (YTD) PRICE, TOTAL RETURN, AND 5-YEAR STOCK BETA OF

KEY VENDORS  186

FIGURE 45            EV/EBITDA OF KEY VENDORS   187

FIGURE 46            ORGAN PRESERVATION MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS     187

FIGURE 47            XVIVO PERFUSION AB: COMPANY SNAPSHOT (2024)    197

FIGURE 48            TRANSMEDICS, INC.: COMPANY SNAPSHOT (2024)    205

FIGURE 49            BIOLIFE SOLUTIONS, INC.: COMPANY SNAPSHOT (2024)             211

MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。

※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

ライセンスタイプ4

ミニレポート　※定性調査にフォーカスした調査レポートです。詳細はお問合せください。

ご購入に関するご案内

価格・納期について

• 価格
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • マルチユーザライセンス
    • 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
  • コーポレートライセンス
    • 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
  • エンタープライズサイトライセンス
    • 特別ライセンスです。適用範囲についてはお問合せください。
• 納品形態
  • Eメール
• 納期
  • 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。

最新調査レポート

• 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
• 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
• ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11

MarketsandMarkets  出版レポート一覧